Tumor Necrosis Factor Receptor Superfamily, Member 11b (TNFRSF11B) antibody

Details for Product No. ABIN108498, Supplier: Log in to see
Antigen
  • OCIF
  • OPG
  • TR1
  • BTF3L1
  • HUMBTFB
  • TNFRSF11B
  • Opg
  • ocif
  • opg
  • tr1
  • tumor necrosis factor receptor superfamily, member 11b
  • basic transcription factor 3 pseudogene 11
  • tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)
  • osteoprotegerin
  • TNFRSF11B
  • BTF3P11
  • Tnfrsf11b
  • LOC100037695
  • tnfrsf11b
Reactivity
Human
172
42
26
4
3
3
3
1
1
1
Host
Mouse
95
68
7
2
1
Clonality (Clone)
Monoclonal ()
Conjugate
Un-conjugated
10
5
5
5
4
4
1
1
1
1
1
1
1
1
1
1
1
1
1
Application
Western Blotting (WB)
154
80
72
47
41
34
28
18
12
12
3
2
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Immunogen
  • The antibody is a mouse monoclonal antibody against recombinant Human Osteoprotegerin. The human Osteoprotegerin is a OPG Fc.
  • Source of Immunogen: E. coli
Clone OPG-01
Isotype IgG1 kappa
No Cross-Reactivity Human
Cross-Reactivity (Details) Not yet tested in other species.
Purification Affinity chromatography on a column with immobilized protein G.
Alternative Name Osteoprotegerin (TNFRSF11B Antibody Abstract)
Background
  • Osteoprotegerin (OPG) or osteoclastogenesis inhibitory factor (OCIF) is a secretory glycoprotein belonging to TNF receptor superfamily. OPG consists of 401 amino acid residues, it has a molecular weight of 60 kDa as a monomer and 120 kDa as a disulfide-linked dimer and is produced in different tissues, e.g. bone, skin, liver, stomach, intestine and lung. Osteoprotegerin inhibits the recruitment, proliferation and activation of osteoclasts. Osteoclast formation activity may be monitored principally by determination of concentration ratio of osteoprotegerin ligand (OPGL)/OPG. Alteration of this ratio may be the cause of bone loss in many imbalances in bone metabolism such as osteoporosis, osteopetrosis, hypercalcemia, metastatic osteolytic lesions and rheumatic bone degradation.
  • Other Names: OPG, Osteoclastogenesis inhibitory factor, OCIF
  • Research Areas: Bone and cartilage metabolism
Research Area Cardiovascular, Atherosclerosis, Extracellular Matrix, Innate Immunity, Cytokines
Application Notes
  • Quality control: Indirect ELISA - to determine titer of the antibody SDS PAGE - to determine purity of the antibody
  • Otimal working dilution should be determined by the investigator.
Restrictions For Research Use only
Format Lyophilized
Reconstitution Add 0.1 mL of deionized water and let the lyophilized pellet dissolve completely. Slight turbidity may occur after reconstitution, which does not affect activity of the antibody. In this case clarify the solution by centrifugation
Buffer The antibody is lyophilized in 0.05 M phosphate buffer, 0.1 M NaCl, pH 7.2. AZIDE FREE.
Preservative Azide free
Storage 4 °C/-20 °C/-80 °C
Storage Comment The lyophilized antibody remains stable and fully active until the expiry date when stored at -20 °C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles and store frozen at -80 °C. Reconstituted antibody can be stored at 4 °C for a limited period of time, it does not show decline in activity after one week at 4 °C.
Expiry Date See label
Background publications Kwan Tat S,Padrines M,Theoleyre S,Heymann D,Fortun Y: "IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology." in: Cytokine Growth Factor Rev, Vol. 15, Issue 1, pp. 49-60, 2004 (PubMed).

Kaden JJ,Bickelhaupt S,Grobholz R,Haase KK,Sarikoc A,Kilic R,Brueckmann M,Lang S,Zahn I,Vahl C,Hagl S,Dempfle CE,Borggrefe M: "Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification." in: J Mol Cell Cardiol, Vol. 36, Issue 1, pp. 57-66, 2004 (PubMed).

Skoumal M,Kolarz G,Woloszczuk W,Hawa G,Klingler A: "Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis." in: Ann Rheum Dis, Vol. 63, Issue 2, pp. 216-7, 2004 (PubMed).

Yasuda, Shima, Nakagawa, Mochizuki, Yano, Fujise, Sato, Goto, Yamaguchi, Kuriyama, Kanno, Murakami, Tsuda, Morinaga, Higashio: "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro." in: Endocrinology, Vol. 139, Issue 3, pp. 1329-37, 1998 (PubMed).

Simonet, Lacey, Dunstan, Kelley, Chang, Lüthy, Nguyen, Wooden, Bennett, Boone, Shimamoto, DeRose, Elliott, Colombero, Tan, Trail, Sullivan, Davy, Bucay, Renshaw-Gegg, Hughes, Hill, Pattison, Campbell et al.: "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. ..." in: Cell, Vol. 89, Issue 2, pp. 309-19, 1997 (PubMed).

Did you look for something else?